ETON at a glance
Eton Pharmaceuticals, Inc. (ETON, SEC CIK 1710340) filed its latest 10-K annual report on March 19, 2026, a 10-Q quarterly report on August 13, 2026, an 8-K current report on September 28, 2026 and Form 4 insider filings as recently as October 6, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Eton Pharmaceuticals, Inc. (ETON) reported revenue of $80.0 million (up 104.9% from FY2024) and a net loss of $4.6 million. Diluted EPS was -$0.17.
- As of June 30, 2026, 24 institutional investment managers tracked by SignalX reported holding Eton Pharmaceuticals, Inc. (ETON) shares worth $219.2 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Krempa David on October 6, 2026 of 4,166 shares at $55.07 per share.
- In the last 90 days, ETON insiders reported 0 open-market purchases ($0) and 11 open-market sales ($12.0M) on Form 4, a net sale of $12.0M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $80.0M
- +104.9% vs prior year
- Insiders · 90 days
- 0 buys · 11 sells
- Net −$12.0M
- 13F holders
- 24 funds
- $219.2M · +2 vs prior quarter
- Latest 8-K
- Sep 28, 2026
- Item 8.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Q2 revenue $37.589M, up $18.661M YoY from $18.928M
- Gross margin 67.6% vs 63.0% YoY, based on gross profit of $25.413M vs $11.924M
- Best performers INCRELEX®, GALZIN®, Carglumic Acid and HEMANGEOL® additions; no product-level figures disclosed
- Cash $26.8M at June 30; operating cash flow $14.660M vs $10.049M YoY
- $15.070M investing outflow, including $14.000M HEMANGEOL® rights acquisition and $1.000M licensing payment
Risk Factors
- No Risk Factors section provided; filing excerpt contains Items 2–6 and signatures only
- Cashless warrant exercises issued 296,215 shares at weighted average exercise price of $31.83
- Warrant exercises generated no cash proceeds and surrendered 62,901 warrants
- Sixth Amendment to Credit Agreement with SWK Funding LLC dated April 6, 2026
- Asset Purchase Agreement with Knight Therapeutics Europe S.A. dated May 18, 2026
AI summary of the ETON 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 8.01: Other Events
- IMPAVIDO® (miltefosine) capsules launched, adding a commercial product to Eton’s portfolio
- Full Eton Cares support includes $0 copay for eligible commercially insured patients
Item 2.02: Results of Operations and Financial Condition
- Press release presents Adjusted EBITDA as a non-GAAP performance metric alongside U.S. GAAP results
- Management uses Adjusted EBITDA for budgeting, internal projections, strategy evaluation and board communications
Item EX-99.1: Item EX-99.1
- U.S. rights license for ASN-001 expands Eton’s infantile hemangioma franchise beyond HEMANGEOL’s systemic-treatment segment
- Phase II/III results: week-24 elimination or near-elimination rates of 56% BID and 42% TID versus 15% placebo
Item 1.01: Entry into a Material Definitive Agreement
- $3.0M upfront license fee due within 30 days for late-stage rare disease candidate ASN-001
- Bioavailability bridging study required before planned NDA submission in 2H 2027
AI summaries of ETON 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for ETON
Don't miss the next ETON filing
- Alerts as it files. A push when ETON files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut ETON, by share count.
- Ask anything. An AI agent that reads every ETON filing and answers with sources.
ETON alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Krempa David | Sell | Oct 6, 2026 | 4,166 | $55.07 |
| Krempa David | M | Oct 2, 2026 | 10,522 | - |
| Krempa David | M | Oct 2, 2026 | 10,522 | - |
| MAIER PAUL V | M | Aug 28, 2026 | 12,500 | $7.31 |
| MAIER PAUL V | M | Aug 28, 2026 | 50,000 | $3.78 |
| MAIER PAUL V | M | Aug 28, 2026 | 50,000 | - |
| MAIER PAUL V | M | Aug 28, 2026 | 12,500 | - |
| MAIER PAUL V | Sell | Aug 28, 2026 | 128 | $61.77 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $39.0M | $80.0M |
| Gross Profit | - | $23.4M | $42.7M |
| Operating Income | - | -$2.6M | -$844K |
| Net Income | - | -$3.8M | -$4.6M |
| Gross Margin | - | 60.0% | 53.5% |
| Op. Margin | - | -6.7% | -1.1% |
| Net Margin | - | -9.8% | -5.8% |
| Balance Sheet | |||
| Total Assets | $31.7M | $76.1M | $92.1M |
| Equity | $15.5M | $24.4M | $26.2M |
| ROE | - | -15.7% | -17.6% |
| Per Share | |||
| EPS | - | $-0.15 | $-0.17 |
| Cash Flow | |||
| Operating CF | - | $969K | $10.5M |
| CapEx | - | $26K | $333K |
Source: XBRL data in Eton Pharmaceuticals, Inc. (ETON)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate ETON share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 24 | $219.2M |
| Q1 2026 | 22 | $128.3M |
| Q4 2025 | 22 | $92.5M |
| Q3 2025 | 20 | $134.5M |
| Q2 2025 | 18 | $74.9M |
| Q1 2025 | 15 | $34.6M |
| Q4 2024 | 10 | $24.4M |
| Q3 2024 | 5 | $1.9M |
- Morgan Stanley+290.0K (+61%)
- BlackRock+178.5K (+10%)
- State Street Corp+171.6K (+32%)
- Wells Fargo & Co+105.1K (+1099%)
- Vanguard Portfolio Management LLC+42.8K (+28%)
- Renaissance Technologies LLC−111.0K (-68%)
- Goldman Sachs Group−84.9K (-39%)
- Citadel Advisors LLC−58.8K (-55%)
- Vanguard Capital Management LLC−17.5K (-2%)
- Bank of America Corp−2.1K (-1%)
- D.E. Shaw & Co+188.5K
- Dimensional Fund Advisors+42.5K
- Prudential Financial+21.1K
- Millennium Management−14.9K
Source: 13F-HR filings on SEC EDGAR (aggregated from 136 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
ETON filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Oct 6, 2026 | - | - | - |
| 8-K | Sep 28, 2026 | - | Analysis | - |
| 4 | Aug 31, 2026 | - | - | - |
| 4 | Aug 28, 2026 | - | - | - |
| 4 | Aug 24, 2026 | - | - | - |
| 4 | Aug 20, 2026 | - | - | - |
| 8-K | Aug 13, 2026 | - | Analysis | - |
| 10-Q | Aug 13, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 5, 2026 | - | Analysis | - |
| 4 | Aug 4, 2026 | - | - | - |
| 4 | Aug 4, 2026 | - | - | - |
| 4 | Aug 4, 2026 | - | - | - |
| 8-K | Aug 4, 2026 | - | Analysis | - |
| 4 | Aug 4, 2026 | - | - | - |
| 4 | Aug 4, 2026 | - | - | - |
| 4 | Aug 4, 2026 | - | - | - |
| 4 | Aug 4, 2026 | - | - | - |
| 4 | Aug 4, 2026 | - | - | - |
| 8-K | Jul 29, 2026 | - | Analysis | - |
| 4 | Jul 17, 2026 | - | - | - |
| 4 | Jul 16, 2026 | - | - | - |
| 4 | Jul 14, 2026 | - | - | - |
| 4 | Jul 13, 2026 | - | - | - |
| 4 | Jul 7, 2026 | - | - | - |
| 4 | Jun 30, 2026 | - | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
ETON SEC filings: frequently asked questions
Are ETON insiders buying or selling?
In the last 90 days, Eton Pharmaceuticals, Inc. (ETON) officers, directors and 10% owners reported no open-market purchases and 11 open-market sales worth $12.0 million by 4 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold ETON stock?
As of June 30, 2026, the largest Eton Pharmaceuticals, Inc. (ETON) holders among the 13F filers tracked by SignalX were BlackRock ($68.6 million), Vanguard Capital Management LLC ($35.4 million), Morgan Stanley ($27.8 million), State Street Corp ($25.4 million), Northern Trust ($9.3 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was ETON's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Eton Pharmaceuticals, Inc. (ETON) reported revenue of $80.0 million (up 104.9% from FY2024) and a net loss of $4.6 million. Diluted EPS was -$0.17. The figures come from the XBRL data in the 10-K.
What did ETON report in its latest 8-K?
Eton Pharmaceuticals, Inc. (ETON) filed an 8-K on September 28, 2026 reporting Item 8.01 (Other Events). IMPAVIDO® (miltefosine) capsules launched, adding a commercial product to Eton’s portfolio.
What are the latest ETON SEC filings?
Eton Pharmaceuticals, Inc. (ETON) filed its latest 10-K annual report on March 19, 2026, a 10-Q quarterly report on August 13, 2026, an 8-K current report on September 28, 2026 and a Form 4 insider filing on October 6, 2026.
What is ETON's SEC CIK number?
Eton Pharmaceuticals, Inc. (ETON)'s SEC Central Index Key (CIK) is 1710340. EDGAR lists every ETON filing under that number.
Ask anything about ETON
The research agent reads ETON's filings, financials, insider trades and 13F holders, then answers with sources.